Gilead Hep-C pipeline drug hits speed bump: relapse in genotype 1 null responders
This article was originally published in Scrip
Executive Summary
Shares of Gilead Sciences took a dive after the company announced that in the genotype 1 null responder cohort of the ongoing Phase II ELECTRON study, certain patients relapsed within four weeks of completing 12 weeks on a two-drug regimen of Gilead's experimental hepatitis C drug GS-7977, a nucleoside analogue, plus ribavirin.